Samsung Biologics expands service, adding mRNA vaccines to its range

1 June 2021

South Korean contract development and manufacturing organization (CDMO) Samsung Biologics (KRX: 207940.KS) plans to add mRNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022.

mRNA has been the technology of choice for many COVID-19 vaccines due to its characteristics of safety, and fast scalability in manufacturing. This technology is the bases of COVID-19 vaccines from Pfizer (NYSE: PFE)/BioNTech (Nasdaq: BNTX), CureVac (Nasdaq: CVAC) and Moderna (Nasdaq: MRNA), with the latter signing a fill-finish manufacturing deal with Samsung Biologics last month.

As part of the company's long-term strategy to become a fully-integrated global biopharmaceutical company, Samsung Biologics has been expanding its business portfolio and production capacity to meet the rapidly rising market demand beyond its current business focused on monoclonal antibodies (MAbs).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK